Inclisiran
Inclisiran (development codes ALN-PCSsc, ALN-60212) is an experimental drug for the treatment of familial hypercholesterolaemia. It is a small interfering RNA that inhibits translation of the protein PCSK9.[1][2][3] It is being developed by The Medicines Company which licensed the rights to inclisiran from Alnylam Pharmaceuticals.[4] According to the Department of Health and Social Care, this cure would annually prevent 55,000 heart attacks and strokes for every 300,000 patients.[5]
In 2019 The Medicines Company announced positive results from pivotal phase 3 study (all primary and secondary endpoints were met with efficacy consistent with Phase 1 and 2 studies). The company anticipates regulatory submissions in the U.S. in the fourth quarter of 2019 and in Europe in the first quarter of 2020.[6] The Medicines Company is being acquired by Novartis.Vorlage:Fact
References
Vorlage:Cardiovascular-drug-stub
- ↑ Kevin Fitzgerald, Suellen White, Anna Borodovsky, Brian R Bettencourt, Andrew Strahs, Valerie Clausen, Peter Wijngaard, Jay D Horton, Jorg Taubel, Ashley Brooks, Chamikara Fernando, Robert S Kauffman, David Kallend, Akshay Vaishnaw, Amy Simon: A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. In: New England Journal of Medicine. 376. Jahrgang, Nr. 1, 2017, S. 41–51, doi:10.1056/NEJMoa1609243, PMID 27959715, PMC 5778873 (freier Volltext).
- ↑ H Spreitzer: Neue Wirkstoffe: Inclisiran. In: Österreichische Apotheker-Zeitung. Nr. 19/2017, 11. September 2017.
- ↑ Proposed INN: List 114. In: WHO Drug Information. 29. Jahrgang, Nr. 4. WHO, 2015, S. 531 f. (who.int [PDF]).
- ↑ Medicines Company's PCSK9 drug hits phase 3 efficacy goals. In: FierceBiotech. Abgerufen am 29. August 2019 (englisch).
- ↑ NHS to pioneer cholesterol-busting jab. In: BBC News. 13. Januar 2020.
- ↑ The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran. In: www.themedicinescompany.com. Abgerufen am 29. August 2019 (englisch).
